Download PDF
CC BY 4.0 · Indian J Med Paediatr Oncol 2024; 45(01): 064-065
DOI: 10.1055/s-0043-1772710
Images in Oncology

Clinical Syndrome of Seizures, Headache, and Visual Blurring in Metastatic Carcinoma Colon

Lakshmi Raj
1   Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
T.M. Anoop 
1   Department of Medical Oncology, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
,
Rakesh CA
2   Department of Radiodiagnosis, Regional Cancer Centre, Thiruvananthapuram, Kerala, India
› Author Affiliations Funding None.
› Further Information
Also available at
   Permissions and Reprints

Abstract

A 51-year-old lady diagnosed as a case of metastatic carcinoma colon stage IV involving lung and left adrenal metastasis was initiated with palliative chemotherapy with FOLFOX-6 chemotherapy infusion regimen that consisted of 5-flurouracil, calcium leucovorin, and oxaliplatin and injection bevacizumab was added to cycle seven of FOLFOX-6 chemotherapy. After 2 months of initiating bevacizumab, she was presented with one episode of generalized tonic clonic seizure, headache, and visual blurring of 2 days duration and magnetic resonance imaging brain T2 fluid-attenuated inversion recovery image revealed subcortical white matter edema in bilateral frontoparietal, occipital, left temporal lobes (Fig. 1A and B), and hyperintense edema with effacement of folia in both cerebellum with nodular areas of contrast enhancement suggestive of posterior reversible encephalopathy syndrome.

Keywords

bevacizumab - medical oncology - posterior reversible encephalopathy syndrome (PRES) - magnetic resonance imaging

Authors' Contributions

L.R., R.C.A., and T.M.A. were involved in data collection, literature review, manuscript preparation, and final approval


Declaration of Patient Consent

The authors certify that they have obtained all appropriate patient consent forms. In the form, the patient has given their consent for her images and other clinical information to be reported in the journal. The patient understands that their names and initials will not be published, and due efforts will be made to conceal their identity, but anonymity cannot be guaranteed.




Publication History

Article published online:
22 September 2023

© 2023. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Allen JA, Adlakha A, Bergethon PR. Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer. Arch Neurol 2006; 63 (10) 1475-1478
    CrossrefPubMedGoogle Scholar
  • 2 Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354 (09) 980-982 , discussion 980–982
    CrossrefPubMedGoogle Scholar
  • 3 Hamid M, Ghani A, Micaily I, Sarwar U, Lashari B, Malik F. Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. J Community Hosp Intern Med Perspect 2018; 8 (03) 130-133
    CrossrefPubMedGoogle Scholar